HBOT and graft survival in smokers

Why does smoking matter for hair transplant surgery?

Smoking narrows blood vessels through nicotine and reduces the blood's oxygen-carrying capacity through carbon monoxide, while also impairing healing. Newly transplanted grafts have no blood supply of their own for the first days and survive purely on diffusion from surrounding tissue, so a smoker's less-perfused recipient bed delivers less oxygen when grafts need it most.

Smoking affects a hair transplant through the same mechanism it affects any surgical wound. Nicotine is a vasoconstrictor: it narrows small vessels and reduces perfusion in the tissue those vessels supply. Carbon monoxide binds haemoglobin with far greater affinity than oxygen does, reducing the oxygen-carrying capacity of the blood that does arrive. Smoking also impairs several elements of the healing response.

For a hair transplant that combination lands on the recipient area at the worst possible moment. During the first days after surgery, transplanted follicular units have no blood supply of their own and survive on diffusion from the surrounding tissue. That diffusion depends on the perfusion of the bed they are sitting in. A smoker's recipient bed is, in the most literal sense, delivering less oxygen than a non-smoker's.

The same applies at the donor site, where healing of thousands of extraction wounds is also perfusion-dependent.

Is there a theoretical reason HBOT could help smokers specifically?

Yes, in theory: HBOT raises dissolved oxygen in blood plasma, which travels independently of haemoglobin and can partly bypass the carbon monoxide problem that reduces smokers' oxygen delivery. HBOT is an established treatment for carbon monoxide poisoning and perfusion-limited problem wounds. It is a coherent argument, but it has never been tested in smoking patients.

If you accept that framing, smokers look like the group HBOT should help most. The deficit is oxygen delivery to a tissue bed; hyperbaric oxygen raises dissolved oxygen in plasma, which travels independently of haemoglobin and can therefore partly bypass the carbon monoxide problem.

That reasoning has a precedent elsewhere in medicine. Hyperbaric oxygen is an established treatment for carbon monoxide poisoning and for problem wounds where perfusion is the limiting factor, and compromised grafts and flaps appear on the recognised indication list.

It is a coherent argument. It is also entirely untested in this population.

Has HBOT actually been studied in smokers after a hair transplant?

No. No published hair-transplant HBOT study has reported results for smokers separately or enrolled smokers specifically. The only randomised trial had just 17 patients per arm — too few for a meaningful smoking-stratified analysis even if attempted. A clinic claiming HBOT compensates for smoking is making a claim no study actually supports.

No published hair-transplant study of hyperbaric oxygen has reported results for smokers separately, and none has enrolled smokers specifically. The Fan trial randomised 34 patients with grade II-IV alopecia; the published report does not present a smoking-stratified analysis, and with 17 patients per arm it could not meaningfully have done so.

This is worth stating clearly, because the smoker argument is one of the more persuasive-sounding pitches for HBOT and it rests on nothing more than mechanism. A clinic telling you that HBOT will compensate for your smoking is making a claim no study supports.

What intervention actually helps a smoker preparing for a hair transplant?

Stopping smoking before and after surgery is the intervention with a real basis — it costs nothing and reverses the vasoconstriction and carbon monoxide load that reduce perfusion. Most surgeons set a pre- and post-operative stopping window; being honest about smoking also lets them plan a more conservative recipient density.

Stopping smoking before and after surgery is the measure with an actual rationale, and unlike HBOT it costs nothing and addresses the cause rather than a symptom.

Most surgeons ask patients to stop for a period before surgery and to continue abstaining through the early healing phase. The specific window varies between clinics and is a matter for your surgical team, but the direction is not controversial: the vasoconstriction and carbon monoxide load are reversible, and removing them restores perfusion in a way that no adjunct replicates.

• Ask your surgeon for their specific pre- and post-operative stopping window and follow it.
• Nicotine replacement is still nicotine, and therefore still a vasoconstrictor — discuss with your surgical team whether it is acceptable in your case.
• Be honest about your smoking at consultation. A surgeon who knows may moderate density in the recipient area, which is a real and useful adjustment.
• If you cannot stop, that is a reason to consider a more conservative plan, not a reason to buy an adjunct.

What's the risky way HBOT gets marketed to smokers?

The risky pitch is HBOT being used to justify a larger, denser session that would otherwise be inadvisable for a smoker's recipient area. That substitutes an unproven adjunct for the conservative surgical planning smoking calls for, transferring risk to the patient. HBOT in smokers remains an untested hypothesis; quitting smoking is the free, proven intervention.

There is a particular way this gets sold that deserves naming. If HBOT is presented as something that lets a smoker proceed with a large, dense session that would otherwise be inadvisable, that is a worse outcome than not offering it at all.

The vascular risk in a smoker's recipient area is a reason for a more conservative surgical plan. Substituting an unproven adjunct for that conservatism transfers risk to the patient and removes the pressure to make the change that would actually help.

The honest position is that HBOT in smokers is a plausible hypothesis nobody has tested, and that stopping smoking is a proven intervention that is free.

Sources

1. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plastic and Reconstructive Surgery, 2011;127 Suppl 1:131S-141S. pubmed.ncbi.nlm.nih.gov/21200283
2. Undersea and Hyperbaric Medical Society. Indications for Hyperbaric Oxygen Therapy (approved indications list). uhms.org/resources/hbo-indications.html
3. Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
4. Parsley WM, Perez-Meza D. Review of factors affecting the growth and survival of follicular grafts. Journal of Cutaneous and Aesthetic Surgery, 2010;3(2). jcasonline.com
5. Heyboer M, Sharma D, Santiago W, McCulloch N. Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified. Advances in Wound Care, 2017;6(6):210-224. pubmed.ncbi.nlm.nih.gov/28616361

This article summarises published research and standard clinical practice. It is general educational information, not medical advice, and it does not replace the instructions your own surgical team gives you. Where their guidance differs from anything here, follow theirs.